Orthocell shares sharply higher on back of positive results in CelGro® nerve repair clinical study
The regenerative medicine company is now progressing regulatory applications in Australia and will start a US regulatory study shortly.
Company
Gold Anti Trust Action Committee
.:[TICKER]
The Gold Anti-Trust Action Committee was organized in the fall of 1998 to expose, oppose, and litigate against collusion to control the price and supply of gold and related financial instruments. The committee arose from essays by Bill Murphy, a financial commentator on the Internet (LeMetropoleCafe.com), and by Chris Powell, a newspaper editor in Connecticut. Murphy's essays reported evidence of collusion among financial institutions to suppress the price of gold. Powell, whose newspaper had been involved in antitrust litigation, replied with an essay proposing that gold mining and investor interests should act on Murphy's essays by bringing antitrust lawsuits against financial institutions involved in the collusion against gold.
170 stories · page 7 of 9
Emyria teams up with Mind Medicine Australia to develop national care program and data registry for psychedelic-assisted therapies
It will leverage on Emyria’s experience with unregistered medicines for patients with unmet needs across its national network of clinics – Emerald Clinics
Orthocell halted with clinical results pending on use of CelGro® for peripheral nerve repair
The paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ reports positive results from pre-clinical and clinical study results for the CelGro treatment.
Emyria chairman makes strong company endorsement with on market purchases
The chairman has made several purchases this month totalling 775,000 ordinary shares valued at more than $61,267, bringing the total shares held in direct and indirect interests to almost 49.326 million.
Emyria higher on entering data deal with Zelira to support Autism Spectrum Disorder trial
This deal leverages Emyria’s real-world data expertise and national network of clinics – Emerald Clinics - to facilitate patient access.
Emyria boosts capital position with $954,180 R&D tax incentive refund from Australian Government
The funds will be invested into accelerating the commercialisation of Emyria’s data products, technologies and supporting internal data analysis.
Emyria medical director demonstrates faith in biotechnology strategy with on-market purchase
The company has partnered with Mt Sinai Hospital’s Precision Recovery team in New York to support ongoing development of Emyria’s Openly clinical service for the remote monitoring of patients and care coordination.
Emyria in global partnership with Sapphire Medical Clinics to leverage UK clinical and research expertise
It will provide a new source of data to bolster Emyria’s growing cannabinoid data platform and allow Emyria to leverage Sapphire’s resources and infrastructure in the UK to provide services to UK patients.
Emyria uniquely positioned to take the lead in future of medicine as it moves beyond clinics
The healthcare technology and services company is taking a leadership role in digitally-connected and patient-centric healthcare that also generates high-quality clinical evidence where it matters most, in the real world.
Emyria signs real-world data agreement with Zelira Therapeutics for insomnia drug Zenivol
Emyria will provide real-world data that will complement the existing clinical data-pack for Zenivol™ and be used to inform further clinical development and, ultimately, the path to product registration.
Emerald Clinics partners with New York’s Mt Sinai Hospital for Openly platform
The company has partnered with Mt Sinai Hospital’s Precision Recovery team to support ongoing development of Emerald’s Openly clinical service for the remote monitoring of patients and care coordination.
Orthocell has positive CelGro® study results published by prestigious Tissue Engineering Journal
The paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ reports positive results from pre-clinical and clinical study results for the CelGro treatment.
Orthocell at forefront of growing market opportunity in regenerative musculoskeletal treatment
The company’s portfolio of regenerative medicine products have shown in clinical studies and real world evidence to return patients to work, activities of daily living and elite sport pain-free.
Emerald Clinics higher as Openly App registered by TGA as medical device
The Openly technology extends Emerald’s real-world-evidence (RWE) platform and aids Emerald’s clinical team to provide remote health and wellness screening for patients and workforces.
Orthocell’s collagen medical device CelGro hits 300-case milestone under TGA Special Access Scheme
The SAS product use also provides real-world evidence for the safety and efficacy of CelGro®, further validating data collected in clinical trials.
Emerald Clinics set to benefit from interim TGA decision to down schedule CBD
The company’s strategy of generating high-quality clinical evidence on the safety and efficacy of new treatments, including CBD, makes it well-positioned to benefit from the changes announced by the TGA.
Emerald Clinics raises $2.2 million to continue expansion of clinical services
The company achieved a record month in July and closed a major data deal in the UK.
Emerald Clinics in trading halt with capital raising news pending
The company proposes its name change to Emyria Limited will support its expanded offerings in remote chronic disease management, digital health technology development and COVID health screening
Emerald Clinics soars on plans to change name in line with global ambitions and expanded offerings
The company proposes that the name change to Emyria Limited will support its expanded offerings in remote chronic disease management, digital health technology development and COVID health screening.
Emerald Clinics soars on signing real-world evidence contract with UK company Canopy Growth
Emerald will leverage its extensive data expertise to monitor the safety, efficacy and pharmacoeconomics of specific medicinal cannabis products.